A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer

Authors

Parag Jitendra Parikh, Henry Ford Health
Hyun Kim, Washington University School of Medicine in St. Louis
Lauren E Henke, Washington University School of Medicine in St. Louis
Alex T Price, Washington University School of Medicine in St. Louis
et al.

Journal

International Journal of Radiation Oncology*Biology*Physics

Publication Date

11-15-2023

Volume

117

Issue

4

First Page

799

Last Page

808

Document Type

Open Access Publication

DOI

10.1016/j.ijrobp.2023.05.023

Rights and Permissions

Parikh PJ, Lee P, Low DA, Kim J, Mittauer KE, Bassetti MF, Glide-Hurst CK, Raldow AC, Yang Y, Portelance L, Padgett KR, Zaki B, Zhang R, Kim H, Henke LE, Price AT, Mancias JD, Williams CL, Ng J, Pennell R, Pfeffer MR, Levin D, Mueller AC, Mooney KE, Kelly P, Shah AP, Boldrini L, Placidi L, Fuss M, Chuong MD. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2023 Nov 15;117(4):799-808. doi: 10.1016/j.ijrobp.2023.05.023. Copyright 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Recommended Citation

Parikh, Parag Jitendra; Kim, Hyun; Henke, Lauren E; Price, Alex T; and et al., "A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer." International Journal of Radiation Oncology*Biology*Physics. 117, 4. 799 - 808. (2023).
https://digitalcommons.wustl.edu/oa_4/2630